Printer Friendly

Vantia Therapeutics gets GBP4m in series B round.

M2 PHARMA-July 6, 2011-Vantia Therapeutics gets GBP4m in series B round(C)2011 M2 COMMUNICATIONS

6 July 2011 - UK-based pharmaceutical company Vantia Therapeutics announced today that it has raised GBP4m (USD6.4m/EUR4.5m) in a series B round.

The round was co-led by Novo A/S and SV Life Sciences, and included MVM Life Science Partners, all existing investors in Vantia. The funds have been raised to advance the development of Vantia's two clinical candidates, VA106483 for nocturia and VA111913 for dysmenorrhoea, both of which are in Phase II trials.

An exploratory Phase II trial of VA111913 in the treatment of dysmenorrhoea (painful periods) showed promising evidence of reduced pain levels in patients receiving the drug candidate. VA111913 was well tolerated in the study and statistically significant differences between VA111913 treatment and placebo were seen for a number of efficacy endpoints, including treatment preference, and a trend to efficacy was seen in all other relevant endpoints.

VA106483 is currently being investigated as a new treatment for nocturia in a 30-patient clinical trial to evaluate the dose-response in men aged over 65 years with benign prostatic hypertrophy (BPH). This population forms the largest part of the nocturia market and represents the greatest unmet need. The results of this trial are expected in the second half of 2011 and will be used to support the design of pivotal clinical trials.

(GBP1 = USD1.601/EUR1.116)

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2011 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 Pharma
Date:Jul 6, 2011
Words:245
Previous Article:JHP Pharmaceuticals introduces larger pack sizes of Adrenalin, Coly-Mycin M and Pitocin.
Next Article:Evotec, UCB enter into drug discovery collaboration for CNS disorders.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters